Abstract
Objective Dyskinetic cerebral palsy (DCP) encompasses a group of predominantly perinatally acquired complex motor disorders that present with dystonia and/or choreoathetosis and are frequently associated with brain lesions in neuroimaging. Recently, lesion network mapping provided a tool to redefine neurological disorders as circuitopathies. In this study, we aim to assess lesion distribution in DCP and identify a DCP-related network derived from lesions.
Methods Here, we review the literature of MRI findings in DCP and perform literature-based lesion network mapping (LNM). Imaging findings and their anatomical distribution were extracted from literature and quantified according to an established MRI classification system for cerebral palsy. Whole-brain functional connectivity from lesions causing DCP was calculated using a pediatric resting-state functional MRI connectome. Results were contrasted with two control datasets for spatial specificity.
Results Review of 48 selected articles revealed that grey matter injury predominated (51%), followed by white matter injury (28%). In 16% of cases MRI was normal. Subcortical lesions affected the thalamus, pallidum and putamen in >40% of reported patients, respectively. Figures available from 23 literature cases were used to calculate DCP-LNM. The LNM revealed functional connectivity to a wide network including the brainstem, cerebellum, basal ganglia, cingulate, and sensorimotor cortices. Strongest connectivity was found for the motor thalamus.
Interpretation The neural network of DCP identified with LNM includes areas previously implicated in hyperkinetic disorders and highlights the motor thalamus as a common network node. The effects of targeting motor thalamic networks with neuromodulation in DCP should be explored in future trials.
Competing Interest Statement
A.L.A.M., B.A., M.T. and I.-K.M. have no conflicts of interest to declare. A.A.K. has served on advisory boards of Medtronic and has received honoraria and travel support from Medtronic and Boston Scientific outside of this work (both producers of DBS devices). A. K. was PI in the STIM-CP trial which was partly funded by Boston Scientific.
Funding Statement
A.L.A.M., B.A. and A.A.K. are supported by Collaborative Research Centre TRR 295 (Project ID 4247788381) of the 'Deutsche Forschungsgemeinschaft' (DFG). A.A.K. is supported by DFG under Germany's Excellence Strategy EXC2049 390688087 and additionally funded by the Lundbeck Foundation as part of the collaborative project grant 'Adaptive and precise targeting of cortex-basal ganglia circuits in Parkinson's Disease' (Grant Nr. R336-2020-1035). A.K. is funded by the University hospital of Cologne. She holds grants from the medical faculty and the Dr. Hans-Guenther and Dr. Rita Herfort foundation. M.S.T. is supported by the Edmond J. Safra Fellowhip for Movement Disorders of the Michael J. Fox Foundation. The funding sources had no involvement in study design, in the collection, analysis, and interpretation of data; in the writing of the manuscript, and in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data for this manuscript was openly available from following sources that are also provided in the manuscript: pediatric functional connectome https://www.lead-dbs.org/release/download.php?id=PedrsfMRI; FCD lesions used for specificity analyses https://openneuro.org/datasets/ds004199/versions/1.0.4; Code used is available within Lead-DBS/-Connectome software https://github.com/netstim/leaddbs; Lesion tracings and lesion network map are available from the corresponding author upon reasonable request.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
